Document is current
Any future updates will be listed below
-
Authors
Li, Shuya https://orcid.org/0000-0002-7263-0365
Wangqin, Runqi https://orcid.org/0000-0001-8069-3676
Pan, Yuesong https://orcid.org/0000-0003-3082-6789
Jin, Aoming https://orcid.org/0000-0002-7221-5444
Li, Hao https://orcid.org/0000-0002-8591-4105
Schwamm, Lee H
Fisher, Marc
Campbell, Bruce C V https://orcid.org/0000-0003-3632-9433
Parsons, Mark W
Wang, Ziran
Dai, Hongguo
Li, Deyang
Li, Runhui
Wang, Junhai
Wang, David
Wang, Yilong
Zhao, Xingquan https://orcid.org/0000-0001-8345-5147
Li, Zixiao
Zheng, Huaguang https://orcid.org/0000-0001-6400-5474
Xiong, Yunyun https://orcid.org/0000-0003-1353-2295
Meng, Xia
Wang, Yongjun https://orcid.org/0000-0002-9976-2341
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04797013 at ClinicalTrials.govDocuments that mention this clinical trial
Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-II (TRACE II): rationale and design
https://doi.org/10.1136/svn-2021-001074
Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial
https://doi.org/10.1136/svn-2023-002310
Influence of impaired renal function on the outcomes of patients with acute ischaemic stroke treated with intravenous tenecteplase and alteplase: a post hoc analysis of the TRACE-2 trial
https://doi.org/10.1136/svn-2024-003726
Outcomes associated to the time to treatment with intravenous tenecteplase for acute ischaemic stroke: subgroup analysis of the TRACE-2 randomised controlled clinical trial
https://doi.org/10.1136/svn-2023-002694
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (81870905, U20A20358, 82111530203)
Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2019-I2M-5-029)
the National Science and Technology Major Project (2017ZX09304018)
- License Information
